PLoS One: 中国TIMS研究:降低溶栓AIS患者血压可改善预后

2016-05-25 MedSci MedSci原创

背景:急性缺血性卒中(AIS)后血压(BP)升高的治疗仍存在争议。本研究的目的是确定TIMS-中国(溶栓治疗的实施与我国急性缺血性脑卒中监测)数据库中,进行溶栓的AIS患者BP和临床预后之间的关联。方法:受试者为1128例AIS后4.5小时内进行静脉重组组织型纤溶酶原激活剂(静脉注射rt-PA)溶栓的患者。分析,基线,治疗2h和24 h收缩压(SBP)和舒张压(DBP),及从基线的变化情况。研究终

背景:急性缺血性卒中(AIS)后血压(BP)升高的治疗仍存在争议。本研究的目的是确定TIMS-中国(溶栓治疗的实施与我国急性缺血性脑卒中监测)数据库中,进行溶栓的AIS患者BP和临床预后之间的关联。

方法:受试者为1128例AIS后4.5小时内进行静脉重组组织型纤溶酶原激活剂(静脉注射rt-PA)溶栓的患者。分析,基线,治疗2h和24h收缩压(SBP)和舒张压(DBP),及从基线的变化情况。研究终点为:良好预后(90天mRS分数0-1)及症状性颅内出血(SICH)。应用Logistic回归进行分析,BP作为参照组。

结果:AIS患者较低的血压(基线,2 h,24 h)是有益的,与良好预后显著相关。rt-PA治疗 24小时后,与血压轻度下降相比,血压大幅度下降与良好预后相关。rt-PA溶栓2h后,与SBP < 140 mmHg相比,收缩压> 160 mmHg与SICH显著相关。较小的SBP下降相比(1-9mmHg),SBP增加(> 25 mmHg)或无变化与SICH显著相关。

结论:本研究新的证据表明,进行溶栓的AIS患者,24h血压降低与良好预后和SICH出血风险降低相关。应考虑给予溶栓的AIS患者,常规降压治疗。

原始出处:

Wu W, Huo X,et al. Relationship between Blood Pressure and Outcomes in Acute Ischemic Stroke Patients Administered Lytic Medication in the TIMS-China Study. PLoS One. 2016 Feb 1.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1789808, encodeId=3f831e89808a4, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Aug 06 22:59:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634933, encodeId=ff1c1634933d2, content=<a href='/topic/show?id=f8072189cf' target=_blank style='color:#2F92EE;'>#AIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2189, encryptionId=f8072189cf, topicName=AIS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ef022348744, createdName=膀胱癌, createdTime=Fri Dec 30 22:59:00 CST 2016, time=2016-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148202, encodeId=981a1482027c, content=好文值得点赞!继续关注学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Oct 14 14:11:12 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779629, encodeId=b5b11e7962956, content=<a href='/topic/show?id=0cff2190ee' target=_blank style='color:#2F92EE;'>#AIS患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2190, encryptionId=0cff2190ee, topicName=AIS患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Tue Oct 25 06:59:00 CST 2016, time=2016-10-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1789808, encodeId=3f831e89808a4, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Aug 06 22:59:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634933, encodeId=ff1c1634933d2, content=<a href='/topic/show?id=f8072189cf' target=_blank style='color:#2F92EE;'>#AIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2189, encryptionId=f8072189cf, topicName=AIS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ef022348744, createdName=膀胱癌, createdTime=Fri Dec 30 22:59:00 CST 2016, time=2016-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148202, encodeId=981a1482027c, content=好文值得点赞!继续关注学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Oct 14 14:11:12 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779629, encodeId=b5b11e7962956, content=<a href='/topic/show?id=0cff2190ee' target=_blank style='color:#2F92EE;'>#AIS患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2190, encryptionId=0cff2190ee, topicName=AIS患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Tue Oct 25 06:59:00 CST 2016, time=2016-10-25, status=1, ipAttribution=)]
    2016-12-30 膀胱癌
  3. [GetPortalCommentsPageByObjectIdResponse(id=1789808, encodeId=3f831e89808a4, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Aug 06 22:59:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634933, encodeId=ff1c1634933d2, content=<a href='/topic/show?id=f8072189cf' target=_blank style='color:#2F92EE;'>#AIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2189, encryptionId=f8072189cf, topicName=AIS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ef022348744, createdName=膀胱癌, createdTime=Fri Dec 30 22:59:00 CST 2016, time=2016-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148202, encodeId=981a1482027c, content=好文值得点赞!继续关注学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Oct 14 14:11:12 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779629, encodeId=b5b11e7962956, content=<a href='/topic/show?id=0cff2190ee' target=_blank style='color:#2F92EE;'>#AIS患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2190, encryptionId=0cff2190ee, topicName=AIS患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Tue Oct 25 06:59:00 CST 2016, time=2016-10-25, status=1, ipAttribution=)]
    2016-10-14 ylzr123

    好文值得点赞!继续关注学习。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1789808, encodeId=3f831e89808a4, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Aug 06 22:59:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634933, encodeId=ff1c1634933d2, content=<a href='/topic/show?id=f8072189cf' target=_blank style='color:#2F92EE;'>#AIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2189, encryptionId=f8072189cf, topicName=AIS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ef022348744, createdName=膀胱癌, createdTime=Fri Dec 30 22:59:00 CST 2016, time=2016-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148202, encodeId=981a1482027c, content=好文值得点赞!继续关注学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Oct 14 14:11:12 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779629, encodeId=b5b11e7962956, content=<a href='/topic/show?id=0cff2190ee' target=_blank style='color:#2F92EE;'>#AIS患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2190, encryptionId=0cff2190ee, topicName=AIS患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Tue Oct 25 06:59:00 CST 2016, time=2016-10-25, status=1, ipAttribution=)]
    2016-10-25 zsyan

相关资讯

Neurology: 血浆裂解晚期糖基化终末产物受体(cRAGE)水平可预测急性脑缺血患者的预后

目的:为了研究内源性分泌RAGE(esRAGE)和裂解的RAGE(cRAGE)这两种可溶性晚期糖基化终末产物受体(RAGE)与急性缺血性脑卒中(IS)预后的相关性。方法:招募急性缺血性脑卒中病人106人及年龄和性别匹配的对照组患者 150人。应用ELISA检测患者急性缺血卒中发生后48h内和48-72h内血浆总sRAGE和esRAGE的水平。同样也用ELISA检测对照组人群的血浆总sRAGE和es

Biol Sex Differ:中国糖尿病患者急性缺血性卒中患者长期预后存在性别差异

背景:糖尿病已被证实与卒中后不良预后相关。然而糖尿病患者卒中后的预后是否存在性别差异尚不清楚。因此,研究者旨在评估糖尿病患者急性缺血性卒中后长期预后的性别差异。方法:本研究招募了2005年5月到2014年9月中国,天津糖尿病并且发生缺血性卒中的患者。分析卒中后,卒中后3个月,12个月和36个月患者死亡率,mRS > 2,卒中再发的患者的性别差异。结果:这项研究共招募2360名患者。入院脑卒中

Neurosurgery:颈动脉夹层患者可进行血管内治疗

背景:颈动脉夹层(CAD)的患者发生急性缺血性卒中(AIS)后血管内治疗的安全和可行性尚不清楚。目的:报道研究者CAD发生AIS患者进行干预措施,并通过系统性综述CAD的静脉溶栓(IVT)等传统治疗和CAD发生AIS的干预措施相比较。方法:回顾性分析来自两个第三中心的狭窄闭塞的CAD患者,患者NIHSS分数>5并且症状持续<12小时。搜索PubMed数据库系统综述CAD患者的进行IVT

PLoS One:急性缺血性卒中患者,血浆同型半胱氨酸水平与白质高信号相关

背景和目的:总血浆同型半胱氨酸水平(tHcy)和白质高信号(WMH)之间的关系是有争议的,尤其是在急性缺血性卒中患者。本研究调查AIS患者这两者及WMH位置之间的关系。方法:从前瞻性缺血性卒中数据库中选出患者。评估临床数据,血浆tHcy水平和WMHs。应用FaZeKas量表和年龄相关白质改变(ARWMC)视觉分级评估WMHs。应用logistic回归分析调查同型半胱氨酸和WMH之间的相关性。结果:

PLoS One:急性缺血性卒中机械取栓后出血、死亡及预后的预测因子有哪些?

背景:血管内机械血栓切除术是一种新兴的有前景治疗急性缺血性卒中的方法,并且有一些优势。然而,Solitaire取栓后的临床预后的预测数据尚不清楚。研究者试图找出应用Solitaire取栓后,急性缺血性卒中患者临床预后的预测因素。方法:研究者对2010年12月到2013年12月急性缺血性卒中患者进行回顾性分析,这些患者进行了Solitaire取栓质量。研究者评估了人口学资料的影响,3个月不良预后(m

PLoS One:急性缺血性卒中患者,入院体温与三天后闭塞血管再通没有关系

背景:闭塞颅内动脉再通受到温度依赖酶的影响,包括阿替普酶。研究者评估入院体温和再通之间的关系。方法:共有13个中心278名急性缺血性卒中症状开始9个小时内的患者,研究者对其进行入院CT血管造影检查。研究者计算入院体温每升高1摄氏度和三天内再通的关系。结果:80%闭塞动脉发生再通。校正年龄,入院NIHSS分数及阿替普酶治疗后,入院体温和三天再通没有关系()。应用阿替普酶治疗与未治疗的患者结果一致。结